INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,095 | +538.0% | 185,334 | +632.3% | 0.00% | – |
| Q2 2023 | $11,301 | -20.2% | 25,310 | +46.6% | 0.00% | – |
| Q1 2023 | $14,158 | -41.1% | 17,266 | +12.0% | 0.00% | – |
| Q4 2022 | $24,043 | -14.1% | 15,412 | -6.3% | 0.00% | – |
| Q3 2022 | $28,000 | +154.5% | 16,441 | +162.7% | 0.00% | – |
| Q2 2022 | $11,000 | -21.4% | 6,258 | +63.0% | 0.00% | – |
| Q1 2022 | $14,000 | – | 3,840 | +5385.7% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 70 | -90.4% | 0.00% | – |
| Q3 2021 | $5,000 | +25.0% | 727 | +63.7% | 0.00% | – |
| Q2 2021 | $4,000 | +300.0% | 444 | +255.2% | 0.00% | – |
| Q1 2021 | $1,000 | -100.0% | 125 | -100.0% | 0.00% | – |
| Q4 2020 | $2,434,000 | -72.8% | 275,048 | -64.3% | 0.00% | -100.0% |
| Q3 2020 | $8,939,000 | +4604.7% | 770,600 | +10836.7% | 0.00% | – |
| Q2 2020 | $190,000 | -91.4% | 7,046 | -98.2% | 0.00% | – |
| Q3 2018 | $2,221,000 | – | 399,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |